Ultragenyx to Participate at Investor Conferences in September

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare genetic disease therapies, has announced its participation in three major investor conferences in September 2025.

The company's leadership, including Chief Medical Officer Eric Crombez, M.D. and Chief Financial Officer Howard Horn, will participate in fireside chats and host one-on-one meetings at the Cantor Global Healthcare Conference (September 4), Morgan Stanley Global Healthcare Conference (September 9), and Bank of America Global Healthcare Conference (September 23). All fireside chat sessions will be available via webcast on the company's investor relations website.

News Market Reaction

+6.91%

1 alert

+6.91% News Effect

On the day this news was published, RARE gained 6.91%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences.

Cantor Global Healthcare Conference 2025 (New York, NY)

• Thursday, September 4, 2025, Eric Crombez, M.D., Chief Medical Officer and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.
  

Morgan Stanley 23^rd Annual Global Healthcare Conference (New York, NY)

• Tuesday, September 9, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
  

Bank of America Global Healthcare Conference (London, UK)

• Tuesday, September 23, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
  

The live and archived webcast of the fireside chats will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts – Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com

FAQ

When is Ultragenyx (RARE) presenting at the Cantor Global Healthcare Conference 2025?

Ultragenyx will present at the Cantor Global Healthcare Conference on Thursday, September 4, 2025, with CMO Eric Crombez and CFO Howard Horn participating in a fireside chat and hosting 1x1 meetings.

Who will represent Ultragenyx at the September 2025 healthcare conferences?

Eric Crombez, M.D., Chief Medical Officer, will attend all three conferences, while Howard Horn, Chief Financial Officer, will participate in the Cantor Global Healthcare Conference.

How can investors access Ultragenyx's conference presentations in September 2025?

Investors can access the live and archived webcasts of the fireside chats through Ultragenyx's website at https://ir.ultragenyx.com/events-presentations.

Which investor conferences will Ultragenyx (RARE) attend in September 2025?

Ultragenyx will attend three conferences: the Cantor Global Healthcare Conference (Sept. 4), Morgan Stanley Global Healthcare Conference (Sept. 9), and Bank of America Global Healthcare Conference (Sept. 23).